This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Viemed Healthcare, Inc.
11/5/2026
Greetings. Welcome to the ViMed Healthcare third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. I'll now turn the conference over to Trae Fitzgerald, CFO. Thank you, Trae. You may begin.
Thank you, and good morning, everyone. Please note that our remarks in this conference call may include forward-looking statements under the U.S. federal securities laws or forward-looking information under applicable Canadian securities legislation, which we collectively refer to as forward-looking statements. Such statements reflect the company's current views and intentions with respect to future results or events and are subject to certain risks and uncertainties, which could cause actual results or events to vary from those indicated in forward looking statements. Examples of such risk and uncertainties are discussed in our disclosure documents filed with the SEC or the security regulatory authorities in certain provinces of Canada. Because of these risks and uncertainties, investors should not place undue reliance on forward looking statements. forward-looking statements made in this conference call are made as of today and the company undertakes no obligations to update or revise any forward-looking statements except as required by law. The third quarter financial supplement and financial news release as well as the related financial statements are available on the SEC's website. With that, I'll turn the call over to our Chief Executive Officer, Casey Hoyt.
Thank you, Trae. Good morning, everyone, and thank you for joining us. Before getting into the results, I want to thank our roughly 1,500 employees. Their daily work with patients and referral partners is what makes our growth possible. I appreciate the care they provide and the work they put into serving more patients as ViMed continues to grow. The third quarter was another strong quarter for ViMed, with record revenue of $80.7 million, representing 12.2% growth over last year. Just as importantly, that growth translated into stronger earnings. Net income attributable to ViMed increased 32% year-over-year and approximately 68% from the second quarter. We're continuing to grow the business at a double-digit pace, demonstrating the earnings potential of the platform we've built. For the first time since the Leehan acquisition, both the current and prior year quarters include a full three months of Leehan's operations. That gives us a much clearer picture of our growth with the 12.2% increase reflecting expansion across our existing businesses rather than the incremental revenue contribution of an acquisition. Sleep therapy was a particular source of strength this quarter, and we're also seeing encouraging results from bringing maternal health services into our established ViMed markets. The success in those initial maternal health markets gives us confidence to broaden the rollout. We are now on track to enter two additional states per quarter beginning in the fourth quarter, establishing a regular pace of expansion. The markets we have already entered are still early in their development. We see years of opportunity to build volume within each state as we develop referral relationships and reach more patients. Each launch adds to that opportunity so growth can continue within our existing markets as we expand into new ones. Breast pumps and related supplies are a practical example of how we can do more with the capabilities already in the company. Lehan brought the specialized experience in this business. BiMed's existing payer relationships and reimbursement capabilities give us a way to extend it into markets we already know. The early results have given us the confidence to take that next step. As we open those markets, we'll be paying close attention to fulfillment and reimbursement. We want the additional volume to become a productive part of the business with reliable service for mothers who depend on us. The two-state cadence gives our teams a clear operating plan for the next stage. Our growing sleep patient population shows how we're expanding BiMed's reach and serving more people. During the quarter, we served 43,861 pap therapy patients, over 6,000 more than the second quarter, and 37.5% above a year ago. Pap setups also increased both sequentially and year over year. Growth is coming through in patients receiving therapy as well as the activity bringing patients into care. Resupply grew alongside that activity. We served 40,918 resupply patients of approximately 22% from a year ago and 10.5% from the second quarter. Our expanding patient population creates further opportunity to grow resupply and increasing participation in the program is a priority. We are simplifying order processing to support that growth and make it easier for patients to receive supplies on time with the service that keeps them engaged over the course of their therapy. In ventilation, we have a longer revenue trend to assess under the revised CMS coverage rules issued in 2025. Ventilator rental revenue has increased in each quarter this year from $35.4 million to $36.4 million and now $37.5 million. For the first nine months, it was approximately 8% above the same period last year. The comparison is particularly meaningful because much of the comparable 2025 period preceded the new CMS coverage rules. Growing ventilation revenue against that comparison supports our confidence and our ability to expand the business under the new framework. More broadly, we view the legislative and rulemaking environment as generally favorable to establish providers that are invested in clinical care and compliance. Audit activity has increased across the DME industry, including for providers with strong compliance programs. Our own teams are spending more time and resources responding to those reviews. We are encouraged that CMS is examining its audit contractor model and has specifically asked how to reduce unnecessary provider burden and protect patient access. We see an opportunity for more targeted consistent oversight and we intend to bring our experience to that discussion so providers can devote more of their resources to caring for patients. Our responsibility is to help patients receive the care they need. We support appropriate oversight and we will advocate for coverage policies and review processes that preserve timely access to medically necessary care. Our clinical teams see the needs of these patients every day and we intend to make sure those needs remain part of the policy discussions. The third quarter showed that we can grow the business under the new coverage framework and convert more revenue into earnings. We are serving more patients and the opportunities ahead in sleep and maternal health give us the confidence that we can enter the final quarter of the year. Todd will now discuss the financial results and operating priorities supporting our next stage of the growth.
You're reading a preview of the VMD Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing